Yan Yang1, Yan-Ping Wan2, Zhu-Ping Fan3, Xiang Gao4, An-Li Jiang5, Ren-Ying Xu6. 1. School of Nursing, Second Military Medical University, Shanghai, 200433, China. 2. Department of Clinical Nutrition, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China. 3. Department of Digestion, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 4. Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA, USA. 5. School of Nursing, Second Military Medical University, Shanghai, 200433, China. alj1018@aliyun.com. 6. Department of Clinical Nutrition, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China. xurenying7465@126.com.
Abstract
PURPOSE: Whether metabolically healthy obesity (MHO) is associated with longitudinal changes in high-density lipoprotein cholesterol (HDL-C) remains unclear. METHODS: MHO was defined as participants with overweight and obesity (BMI ≥ 24.0 kg/m2, n = 2921), free of history of metabolic diseases, and without abnormalities of blood pressure, fasting blood glucose, hemoglobin A1c, lipid profile, carotid artery and liver ultrasonographic findings at baseline. Metabolically healthy normal weight (MHN) was defined as participants with normal weight (BMI < 24.0 kg/m2, n = 9578) and without above-mentioned abnormalities. HDL-C, fasting blood glucose, hemoglobin A1c, and blood pressure were assessed annually. Glucose abnormality was considered if either FBG ≥ 5.6 mmol/L or HbA1c ≥ 5.7%; while, high blood pressure (HBP) was considered if either systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 80 mmHg during 5 years of follow-up. RESULTS: Compared with the MHN group, the adjusted mean difference in HDL-C change rate was - 0.005 mmol/L per year [95% confidence interval (CI) - 0.007, - 0.003] for MHO after adjustment for a series of potential confounders. Furthermore, transiting to abnormality of blood glucose, but not high blood pressure, was associated with lower cumulative average of HDL-C in MHN group, compared with those remained in metabolically healthy status. CONCLUSIONS: MHO and transiting from metabolically healthy to abnormality of blood glucose were associated with HDL-C in Chinese adults. LEVEL OF EVIDENCE: III, cohort study.
PURPOSE: Whether metabolically healthy obesity (MHO) is associated with longitudinal changes in high-density lipoprotein cholesterol (HDL-C) remains unclear. METHODS: MHO was defined as participants with overweight and obesity (BMI ≥ 24.0 kg/m2, n = 2921), free of history of metabolic diseases, and without abnormalities of blood pressure, fasting blood glucose, hemoglobin A1c, lipid profile, carotid artery and liver ultrasonographic findings at baseline. Metabolically healthy normal weight (MHN) was defined as participants with normal weight (BMI < 24.0 kg/m2, n = 9578) and without above-mentioned abnormalities. HDL-C, fasting blood glucose, hemoglobin A1c, and blood pressure were assessed annually. Glucose abnormality was considered if either FBG ≥ 5.6 mmol/L or HbA1c ≥ 5.7%; while, high blood pressure (HBP) was considered if either systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 80 mmHg during 5 years of follow-up. RESULTS: Compared with the MHN group, the adjusted mean difference in HDL-C change rate was - 0.005 mmol/L per year [95% confidence interval (CI) - 0.007, - 0.003] for MHO after adjustment for a series of potential confounders. Furthermore, transiting to abnormality of blood glucose, but not high blood pressure, was associated with lower cumulative average of HDL-C in MHN group, compared with those remained in metabolically healthy status. CONCLUSIONS: MHO and transiting from metabolically healthy to abnormality of blood glucose were associated with HDL-C in Chinese adults. LEVEL OF EVIDENCE: III, cohort study.
Authors: Feon W Cheng; Xiang Gao; Diane C Mitchell; Craig Wood; David D K Rolston; Christopher D Still; Gordon L Jensen Journal: J Nutr Gerontol Geriatr Date: 2016 Jul-Sep
Authors: Camille Lassale; Ioanna Tzoulaki; Karel G M Moons; Michael Sweeting; Jolanda Boer; Laura Johnson; José María Huerta; Claudia Agnoli; Heinz Freisling; Elisabete Weiderpass; Patrik Wennberg; Daphne L van der A; Larraitz Arriola; Vassiliki Benetou; Heiner Boeing; Fabrice Bonnet; Sandra M Colorado-Yohar; Gunnar Engström; Anne K Eriksen; Pietro Ferrari; Sara Grioni; Matthias Johansson; Rudolf Kaaks; Michail Katsoulis; Verena Katzke; Timothy J Key; Giuseppe Matullo; Olle Melander; Elena Molina-Portillo; Concepción Moreno-Iribas; Margareta Norberg; Kim Overvad; Salvatore Panico; J Ramón Quirós; Calogero Saieva; Guri Skeie; Annika Steffen; Magdalena Stepien; Anne Tjønneland; Antonia Trichopoulou; Rosario Tumino; Yvonne T van der Schouw; W M Monique Verschuren; Claudia Langenberg; Emanuele Di Angelantonio; Elio Riboli; Nicholas J Wareham; John Danesh; Adam S Butterworth Journal: Eur Heart J Date: 2018-02-01 Impact factor: 29.983